Over six months, volunteers received a prime-boost vaccination including six injections, four injections of a vaccine called ALVAC HIV (vCP1521) with the last two being at the same time as two injections of another vaccine called AIDSVAX B/E (gp120). (wikipedia.org)
In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]) plus two booster injections of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E). The vaccine and placebo injections were administered to 16,402 healthy men and women between the ages of 18 and 30 years in Rayong and Chon Buri provinces in Thailand. (emmes.com)
At last year's AIDS Vaccine meeting in Bangkok, investigators shared the first set of results from such analyses, identifying what they called "correlates of risk" associated with the Thai regimen-a vCP1521 canarypox viral vector prime followed by a gp120 B/E AIDSVAX boost. (vaxreport.org)
Gp1204
BACKGROUND: HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled HIV vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent subtype C gp120 Env protein at two dose levels in healthy HIV-uninfected adults. (bvsalud.org)
At months 3 and 6, participants received either placebo, ALVAC-HIV (vCP2438) with 200µg of bivalent subtype C gp120 adjuvanted with MF59 or AS01B, or ALVAC-HIV (vCP2438) with 40µg of bivalent subtype C gp120 adjuvanted with AS01B. (bvsalud.org)
To induce CD8+ cytotoxic T lymphocytes (CTLs) along with neutralizing antibody and CD4+ T cell help, a live canarypox virus construct expressing gp120, transmembrane gp41, the gag and protease genes, and sequences containing CTL epitopes in nef and pol was given simultaneously with, or followed by, rgp120 SF2. (lookformedical.com)
In '09 2009, a big multicenter, double-blind, placebo-controlled scientific research uncovered that priming immunization with ALVAC-HIV (a canarypox vector vaccine expressing HIV Env, Gag, and CMPDA Pro) accompanied by AIDSVAX B/E (a recombinant HIV Env gp120 vaccine) enhancing can decrease the threat of HIV infections among heterosexuals by 31% (38). (cancerhugs.com)
This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk. (emmes.com)
Instead of the classical types of vaccines such as live and inactivated viruses, several novel immunogens including protein subunit and DNA vaccines as well as viral and bacterial vectors are currently being examined. (aerzteblatt.de)
Even if vaccines do not prevent infection, a vaccine strategy that reduces the viral load and thus transmission and slows down the disease process would be epidemiologically useful and probably feasible. (aerzteblatt.de)
Gene-based viral vaccine vectors give a main advantage over proteins vaccines within their capability to induce solid T-cell responses furthermore to antibody replies. (cancerhugs.com)
As an important part of immunotherapy, cancer vaccines have unique and significant advantages against prostate cancer, including monocyte vaccines and dendritic cells,accines, viral vaccines, peptide vaccines and DNA/mRNA vaccines [9]. (asmepress.com)
Replication3
In this scholarly study, we first examined the potential of different prime-boost combos regarding replication-defective lymphocytic choriomeningitis pathogen (rLCMV), a gene-based viral vector that elicits powerful CD8 immune replies (17). (cancerhugs.com)
The peripheral T-cell counts initially surge after therapy is initiated, but this represents redistribution of activated T cells from the viral replication centers in the lymph nodes rather than a true increase in total-body CD4 T-cell counts. (medscape.com)
Quick suppression of the viral load with highly active ART (HAART) substantially slows viral replication and prevents resistant mutations. (medscape.com)
Placebo1
METHODS: Participants received ALVAC-HIV (vCP2438) alone or placebo at months 0 and 1. (bvsalud.org)
Antibody2
The RV144 HIV-1 vaccine trial results showed moderate reduction in viral infections among vaccinees as well as induction of antibody-dependent cellular cytotoxicity and vaccine-specific IgG and IgG3 responses directed at variable loop regions 1 and 2 of the HIV envelope protein. (nih.gov)
Although previous data showed elevated levels of IgG antibodies in both boosting arms, regardless of ALVAC-HIV vector incorporation, the effect on shaping antibody effector function remains unclear. (nih.gov)
Vaccine trial1
The companion vaccine trial RV305 was designed to permit the evaluation of the immunologic impact of late boosting with either the boosting protein antigen alone, the canarypox viral vector ALVAC alone, or a combination of both. (nih.gov)
Genes4
ALVAC‐HIV consists of a viral vector containing genetically engineered versions of three HIV genes (env, gag and pol). (wikipedia.org)
We then inserted the genes encoding lacZ, luciferase (luci), and envelope of human T-lymphotropic virus type 1 (HTLV-1 env) into the TK gene of CaPV to evaluate its suitability as an expression vector. (lookformedical.com)
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. (lookformedical.com)
Infections1
However, neither rFWPV nor rVV were able to express transgenes under the control of late viral promoters, indicating that both rFWPV and rVV infections are arrested at an early stage in human DCs. (lookformedical.com)
Infection1
Vaccination did not affect the viral load or CD4+ count in subjects with HIV infection. (emmes.com)
Protein1
Most functional responses increased upon protein boosting, regardless of the viral vector-priming agent incorporation. (nih.gov)
Immune1
Specifically, the power of prime-boost immunization with heterologous vectors to elicit solid mobile and humoral immune system responses continues to be well noted (7, 18, 23). (cancerhugs.com)
Load1
The inadequacy of merely reducing the viral load has been realized in recent years. (medscape.com)
Virus2
The ALVAC vector is an inert form of canarypox, a bird virus which cannot cause disease or replicate in humans. (wikipedia.org)
We mapped the canarypox virus (CaPV) thymidine kinase (TK) gene within a 5.8-kbp XbaI fragment of the genome by Southern blotting using the fowlpox virus (FPV) TK gene as a probe. (lookformedical.com)
Vaccine vectors2
HIV-1-based lentiviral (LV) vectors have inherent advantages as DC vaccine vectors due to their ability to transduce non-dividing cells and integrate into the target cell genomic DNA, allowing for expression of encoded antigens over the lifespan of the cell. (frontiersin.org)
Currently, the HIV vaccine pipeline is complex and includes developing and testing strategies that differ in the following: vaccine vectors, multiple combinations of HIV antigens from different subtypes, adjuvants, routes of immunizations, vaccination schemes and geographical areas reflecting different genetic makeup ( Excler et al, 2014 ). (nih.gov)
Genetically engineered2
ALVAC‐HIV consists of a viral vector containing genetically engineered versions of three HIV genes (env, gag and pol). (wikipedia.org)
The joint effort has led to the development of a genetically engineered poxvirus (also known as a viral vector) to deliver HIV genetic material into cells. (nih.gov)
Antigens1
As the name of the collaboration indicates, the vectors will encode mosaic HIV antigens, which amalgamate components from diverse viral variants. (i-base.info)
Immunogenicity2
10. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. (nih.gov)
We also discuss advances in LV vector designs that have enhanced DC transduction efficiency, target cell specificity, and immunogenicity, and address potential safety concerns regarding LV vector-based vaccines. (frontiersin.org)
Vaccination1
13. Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. (nih.gov)
Replicate1
The ALVAC vector is an inert form of canarypox, a bird virus which cannot cause disease or replicate in humans. (wikipedia.org)
Reservoirs1
Therapeutic vaccine trials for HIV have also failed to show any sustainable impact on viral load and/or viral reservoirs ( 9 - 14 ). (frontiersin.org)
Boost1
In a significant development for the field, a collaboration known as the mosaic HIV vaccine research program - involving subsidiaries of a major pharmaceutical company, Johnson & Johnson - is also planning efficacy trials of a combination strategy involving viral vectors and a new, improved gp140 envelope protein boost. (i-base.info)
Clinical3
Recent basic and clinical research efforts have broadened our understanding of LV vectors as DC-based vaccines. (frontiersin.org)
In this review, we provide an overview of the pre-clinical and clinical LV vector vaccine studies for treating HIV to date. (frontiersin.org)
Additional viral and bacterial vectors, derived from cytomegalovirus (CMV), listeria monocytogenes, and HIV lentiviral (LV) constructs have shown potential in pre-clinical studies, but safety concerns have slowed their development ( 19 - 22 ). (frontiersin.org)
Responses2
1. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. (nih.gov)
Moreover, LV vectors may express additional immunostimulatory and immunoregulatory proteins that enhance DC function and direct antigen-specific T cells responses. (frontiersin.org)
Trials1
Human trials of HIV vaccines that utilize vector-based antigen delivery approaches have primarily included Adenoviral and Pox vector platforms ( 3 - 11 , 13 ). (frontiersin.org)